← Leaderboards
Puneet Opal
Baylor College Of Medicine
$12,814,603
Attributed
$13,412,687
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,412,687 · 12
By mechanism
R01$9,520,578 · 3
R21$1,229,720 · 3
R61$762,606 · 1
K08$760,284 · 1
R56$510,021 · 1
K02$437,400 · 1
Top collaborators
- Marco Martina2 shared
- Samuel I Stupp2 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Huda Y Zoghbi$38,140,328
- Hugo J Bellen$42,403,967
- Richard Joseph Johnson$17,957,136
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsPhenotypeNeurodegenerative DisordersNeuronsPathologyPolyglutamineCerebellumMutantType 1 Spinocerebellar AtaxiaNerve DegenerationAtaxin-1PlayEventToxic EffectGenesAtaxiaPathologicBehavioralAlzheimer&AposPurkinje CellsCellsAdultPathogenesisS Disease
Grant awards (45)
Understanding the Cellular Basis of Movement Disorders$635,901
R01 · FY2025 · NS · contact PI
Elucidating cellular mechanisms underlying neurodegeneration$562,560
R01 · FY2025 · NS · contact PI
Elucidating cellular mechanisms underlying neurodegeneration$545,684
R01 · FY2024 · NS · contact PI
VEGF-Mimetic Supramolecular Nanoparticles for Treating Spinocerebellar Ataxia Type 1$401,334
R61 · FY2024 · NS · contact PI
Elucidating cellular mechanisms underlying neurodegeneration$575,736
R01 · FY2023 · NS · contact PI
Understanding the Cellular Basis of Movement Disorders$532,040
R01 · FY2023 · NS · contact PI
VEGF-Mimetic Supramolecular Nanoparticles for Treating Spinocerebellar Ataxia Type 1$361,272
R61 · FY2023 · NS · contact PI
Equipment Supplement: Understanding the Cellular Basis of Movement Disorders$18,575
R01 · FY2023 · NS · contact PI
Elucidating cellular mechanisms underlying neurodegeneration$575,736
R01 · FY2022 · NS · contact PI
Understanding the Cellular Basis of Movement Disorders$532,040
R01 · FY2022 · NS · contact PI
Understanding the Cellular Basis of Movement Disorders$532,040
R01 · FY2021 · NS · contact PI
Equipment Supplement: Understanding the Cellular Basis of Movement Disorders$18,951
R01 · FY2021 · NS · contact PI
Understanding the Cellular Basis of Movement Disorders$532,040
R01 · FY2020 · NS · contact PI
ALZHEIMER'S FOCUSED SUPPLEMENT: UNDERSTANDING THE CELLULAR BASIS OF MOVEMENT DISORDERS$379,304
R01 · FY2020 · NS · contact PI
Understanding the Cellular Basis of Movement Disorders$532,040
R01 · FY2019 · NS · contact PI
Understanding pathophysiological mechanisms underlying neurodegeneration$510,021
R56 · FY2019 · NS · contact PI
TRPC3 channels as pharmacological targets for the treatment of ataxia$197,500
R21 · FY2018 · NS
Developing novel treatment strategies for Spinocerebellar ataxia type 1$197,500
R21 · FY2018 · NS · contact PI
Understanding the cellular basis of Movement Disorders$378,780
R01 · FY2017 · NS · contact PI
TRPC3 channels as pharmacological targets for the treatment of ataxia$236,063
R21 · FY2017 · NS
Developing novel treatment strategies for Spinocerebellar ataxia type 1$235,313
R21 · FY2017 · NS · contact PI
Understanding the cellular basis of Movement Disorders$378,780
R01 · FY2016 · NS · contact PI
Understanding the cellular basis of Movement Disorders$378,780
R01 · FY2015 · NS · contact PI
Understanding the cellular basis of Movement Disorders$374,993
R01 · FY2014 · NS · contact PI
Cellular pathways underlying polyglutamine degeneration$323,652
R01 · FY2014 · NS · contact PI
Understanding the cellular basis of Movement Disorders$378,780
R01 · FY2013 · NS · contact PI
Cellular pathways underlying polyglutamine degeneration$315,480
R01 · FY2013 · NS · contact PI
Cellular pathways underlying polyglutamine degeneration$326,922
R01 · FY2012 · NS · contact PI
Cellular pathways underlying polyglutamine degeneration$326,922
R01 · FY2011 · NS · contact PI
Role of Leucine-rich Acidic Proteins in Neuronal Development$73,200
R03 · FY2011 · HD · contact PI
Cellular pathways underlying polyglutamine degeneration$31,248
R01 · FY2011 · NS · contact PI
Cellular pathways underlying polyglutamine degeneration$333,594
R01 · FY2010 · NS · contact PI
Role of Leucine-rich Acidic Proteins in Neuronal Development$76,250
R03 · FY2010 · HD · contact PI
Histone acetylation and neurite outgrowth in Spinocerebellar ataxia type 1$165,156
R21 · FY2009 · NS · contact PI
Histone acetylation and neurite outgrowth in Spinocerebellar ataxia type 1$198,188
R21 · FY2008 · NS · contact PI
Molecular Basis of Spinocerebellar Ataxia Type 1$145,800
K02 · FY2007 · NS · contact PI
Molecular Basis of Spinocerebellar Ataxia Type 1$145,800
K02 · FY2006 · NS · contact PI
Molecular Basis of Spinocerebellar Ataxia Type 1$145,800
K02 · FY2005 · NS
UNDERSTANDING SPINOCEREBELLAR ATAXIA TYPE 1 PATHOGENESIS$126,714
K08 · FY2005 · NS
UNDERSTANDING SPINOCEREBELLAR ATAXIA TYPE 1 PATHOGENESIS$126,714
K08 · FY2004 · NS
UNDERSTANDING SPINOCEREBELLAR ATAXIA TYPE 1 PATHOGENESIS$126,714
K08 · FY2003 · NS
UNDERSTANDING SPINOCEREBELLAR ATAXIA TYPE 1 PATHOGENESIS$126,714
K08 · FY2002 · NS
UNDERSTANDING SPINOCEREBELLAR ATAXIA TYPE 1 PATHOGENESIS$126,714
K08 · FY2001 · NS
UNDERSTANDING SPINOCEREBELLAR ATAXIA TYPE 1 PATHOGENESIS$126,714
K08 · FY2000 · NS
PATHOGENESIS OF SPINOCEREBELLAR ATAXIA TYPE 1$42,628
F32 · FY2000 · NS